| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Anorexia Nervosa; Cachexia; Child Nutrition Disorders; Nausea; Neoplasms; Nutrition Disorders; Sarcopenia; Vomiting | 詳細 | |
| Cannabidiol soft-gel (Avecho Biotechnology) | CBD-TPM | Phase 3 Clinical | Avecho Biotechnology Ltd | Sleep Initiation and Maintenance Disorders | 詳細 |
| Cannabidiol Gel (Zynerba) | ZYN002; ZYN-002 | Phase 3 Clinical | Zynerba Pharmaceuticals Inc | DiGeorge Syndrome; Fragile X Syndrome | 詳細 |
| Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Accidental Injuries; Back Pain; Brachial Plexus Neuropathies; Brain Injuries, Traumatic; Chronic Pain; Diabetes Mellitus; Diabetic Neuropathies; Diabetic peripheral neuropathy; Low Back Pain; Multiple Sclerosis; Neuralgia; Pain; Pain, Postoperative; Paraplegia; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Phantom Limb; Somatoform Disorders; Stroke | 詳細 |
| Dronabinol(Vertanical) | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | 詳細 |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Myocarditis; Pericarditis | 詳細 | |
| Selonabant | V-24343; ANEB-001; VER-24343 | Phase 2 Clinical | Vernalis Plc | Obesity; Poisoning | 詳細 |
| 11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Obesity; Substance-Related Disorders | 詳細 |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Dermatitis, Atopic; Psoriasis; Vitiligo | 詳細 |
| Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Diabetic Gastroparesis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic | 詳細 |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Anorexia; Cachexia; Low Back Pain; Pain; Weight Loss | 詳細 |
| AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | 詳細 |
| Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Diabetic Nephropathies; Metabolic Diseases; Metabolic Syndrome; Obesity | 詳細 |
| Cannabidiol (Ananda Scientific) | A-1002-N5S; A1002N5S | Phase 2 Clinical | Ananda Scientific Inc | Chronic Pain; Opioid-Related Disorders; Stress Disorders, Post-Traumatic; Tobacco Smoking; Tobacco Use Disorder | 詳細 |
| Cannabidiol (Biopharmaceutical Research Company) | BRC-001 | Phase 2 Clinical | Biopharmaceutical Research Company | Breast Neoplasms; Carcinoma, Ductal, Breast | 詳細 |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | 詳細 | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | 詳細 | |
| Suvadronabinol | THC-VHS-NEC; SBI-100; NB-1111; Sb-100 OE; SBI-100 OE; THCVHS; THCVHS-N; THCVHS-NE; UM-5050 | Phase 2 Clinical | University Of Mississippi | Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension | 詳細 |
| IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Alzheimer Disease; Dementia; Psychomotor Agitation | 詳細 |
| Lixosicone | AEF-0117 | Phase 2 Clinical | Aelis Farma, National Institute On Drug Abuse | Marijuana Abuse | 詳細 |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Fibromyalgia; Neuralgia | 詳細 |
| Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Dyslipidemias; Hypercholesterolemia; Hyperglycemia; Metabolic Syndrome; Obesity, Morbid | 詳細 |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | 詳細 |
| Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | 詳細 |
| Cannabidiol (Artelo Biosciences) | ART-12.11; ART12.11; ART-1211 | Phase 1 Clinical | Artelo Biosciences Inc | Anxiety; Depression; Depressive Disorder | 詳細 |
| S1-221 | S1-221 | Phase 1 Clinical | Delphian Therapeutics Australia Pty Ltd | 詳細 | |
| Cannabidiol (Tiamat Australia) | MRX-1 | Phase 1 Clinical | Tiamat Australia Pty Ltd | 詳細 | |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | 詳細 | |
| TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | 詳細 |
| INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | 詳細 |
| IPI 201(Isosceles Pharmaceuticals Inc ) | IPI-201 | Phase 1 Clinical | Pain, Postoperative | 詳細 | |
| CRB-913 | CRB-913 | Phase 1 Clinical | Jenrin Discovery LLC | Obesity | 詳細 |
| GFB-024 | Phase 1 Clinical | Takeda Pharma | Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Endocrine System Diseases; Kidney Diseases | 詳細 | |
| DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | 詳細 | |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | 詳細 |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Anxiety Disorders; Mood Disorders | 詳細 |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | 詳細 | |
| Cannabidiol/Palmitoylethanolamide | SCI–210; THX-210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | delta-9-THC/CBD; MPL-001; MPL-005; PPP-011; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT; GW-1000; KL16-012; THC-5 | Approved | Gw Pharmaceuticals | Sativex, Qixleef, QIXLEEFTM | Canada | Cancer Pain; Chronic Pain; Muscle Spasticity; Neuralgia; Multiple Sclerosis | null | 2005-04-01 | Acute Pain; Agitation; Agoraphobia; Anorexia; Anxiety Disorders; Arthritis, Psoriatic; Arthritis, Rheumatoid; Back Pain; Cancer Pain; Cerebral Palsy; Chronic Pain; Corticobasal degeneration; Dementia; Depression; Depressive Disorder, Major; Diabetic Neuropathies; Drug Resistant Epilepsy; Essential Tremor; Genital Diseases, Male; Healthy Aging; Hepatic Insufficiency; Hidradenitis Suppurativa; Huntington Disease; Kidney Diseases; Low Back Pain; Malnutrition; Marijuana Abuse; Marijuana Use; Migraine Disorders; Multiple Sclerosis; Muscle Spasticity; Neck Pain; Neoplasms; Neuralgia; Neuralgia, Postherpetic; Neuromyelitis Optica; Opioid-Related Disorders; Osteoarthritis, Knee; Pain; Panic Disorder; Peripheral Nervous System Diseases; Phobia, Social; Psoriasis; Reflex Sympathetic Dystrophy; Renal Insufficiency; Renal Insufficiency, Chronic; Sciatica; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Social Behavior; Spasm; Spinal Cord Injuries; Squamous Cell Carcinoma of Head and Neck; Stress Disorde | 詳細 |
| Cannabidiol | CHI-902; APH-1501; GLA-015; BTX-1503; BTX-1801; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; PTL-101; BTX-1702; PBX-1308; BRCX-014; LYT-310; GWP-42003 | Approved | Gw Pharmaceuticals Plc | Epidyolex, Cannepil, Epidiolex | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Acne Vulgaris; Acute Pain; Alcohol Abstinence; Alcoholic Intoxication; Alcoholism; Anemia, Sickle Cell; Anorexia Nervosa; Anxiety; Anxiety Disorders; Appetitive Behavior; Arthralgia; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autism Spectrum Disorder; Autistic Disorder; Azotemia; Behavior, Addictive; Bipolar Disorder; Blepharospasm; Brain Diseases; Brain Injuries, Traumatic; Breast Neoplasms; Bruxism; Burnout, Psychological; Cachexia; Carcinoma, Non-Small-Cell Lung; Carpal Tunnel Syndrome; Central Nervous System Diseases; Child Behavior Disorders; Chronic Pain; Chronic Periodontitis; Chronic Urticaria; Cicatrix; Cognition Disorders; Cognitive Dysfunction; Colitis, Ulcerative; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Corticobasal degeneration; Craving; Crohn Disease; Cystitis, Interstitial; Dentin Sensitivity; Depression; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Driving Under the Influence; Drug Resistant Epilepsy; Dyslipidemias; Dysmenorrhea; Dyspepsia; Eczema; | 詳細 |